AI Assistant
Blog
Pricing
Log In
Sign Up
P478 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
